Coultreon Biopharma
Latest round
- Series A
Last raised
- Apr 2026
Total raised
- $63M
Investors
- 10
About Coultreon Biopharma
Coultreon Biopharma BV, located in Leuven, Belgium, specializes in research and development of advanced therapeutics aimed at treating chronic inflammatory diseases and autoimmune conditions.Founded in 2025, Coultreon Biopharma BV focuses on innovative therapies for chronic inflammatory diseases. The company has not undergone significant pivots in its strategy.Coultreon Biopharma primarily focuses on developing innovative therapeutics for patients suffering from chronic inflammatory diseases, specifically targeting autoimmune conditions. Their core product, COL-5671, is a highly selective SIK3 inhibitor designed to modulate inflammatory pathways while providing a well-tolerated and convenient oral treatment option. This therapeutic aims to provide a multifaceted approach to managing diseases such as ulcerative colitis by simultaneously suppressing pathogenic cytokines like TNFa and IL-12 while promoting anti-inflammatory mediators like IL-10. The company serves a wide range of patients worldwide, particularly in Europe and North America, where there is a pressing demand for more effective oral medications that address significant unmet medical needs.Coultreon Biopharma's revenue structure is primarily derived from the commercialization of its flagship product, COL-5671, along with potential future offerings targeting a range of chronic inflammatory diseases. Revenue transactions are structured around partnerships with healthcare providers, clinical trial agreements, and potential licensing arrangements with pharmaceutical companies. As the company progresses through clinical trials and approaches market readiness, it may consider subscription models or direct sales to hospitals and specialty pharmacies. Pricing plans for COL-5671 would be aligned with industry standards for advanced therapeutics, reflecting its unique mechanism of action and potential for improved patient outcomes. Through these revenue channels, Coultreon aims to establish a solid financial foundation while continuing to drive innovation in the biopharmaceutical sector. Plans to expand into new markets, particularly in North America and Europe, are anticipated by 2027.
Who invested in Coultreon Biopharma
10 investors across 1 round
See all investors in Coultreon Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 28, 2026
Amount
$63M
Investors
Questions about Coultreon Biopharma
Who invested in Coultreon Biopharma?
Coultreon Biopharma has 10 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Coultreon Biopharma raised?
Coultreon Biopharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Coultreon Biopharma last raise money?
Coultreon Biopharma's most recent round on record is a Series A, in Apr 2026.
What does Coultreon Biopharma do?
Coultreon Biopharma BV, located in Leuven, Belgium, specializes in research and development of advanced therapeutics aimed at treating chronic inflammatory diseases and autoimmune conditions.
Where is Coultreon Biopharma headquartered?
Coultreon Biopharma is headquartered in Leuven, Belgium.
Which VCs invest in companies like Coultreon Biopharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Coultreon Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Coultreon Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.